General Information of Drug (ID: DMC0JN8)

Drug Name
GYKI-53655 Drug Info
Synonyms
GYKI-53655; Gyki 53655; GYKI53655; 1-(4-AMINOPHENYL)-3-METHYLCARBAMOYL-4-METHYL-7,8-METHYLENEDIOXY-3,4-DIHYDRO-5H-2,3-BENZODIAZEPINE; 143692-18-6; CHEMBL267450; LY 300168; SMGACXZFVXKEAX-UHFFFAOYSA-N; AC1L2QV0; GYKI-53655 free base; MLS006010331; SCHEMBL351325; GTPL4209; DTXSID30276296; MolPort-006-418-196; BCP27661; BDBM50048386; ABP000447; NCGC00263113-03; NCGC00263113-01; SMR004701394; LY300168; LY-300168; FT-0765288; LY 300168(GYKI 53655); LY-300168, (+/-)-; 7H-1,3-Dioxolo(4,5-H)(2,3)benzodiazepine-7-carboxamide, 5-(4-aminopheny
Cross-matching ID
PubChem CID
126758
CAS Number
CAS 143692-18-6
TTD Drug ID
DMC0JN8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
E-2007 DMJDYNQ Diabetic neuropathy 8C0Z Approved [2]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [3]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [4]
Farampator DM76GRQ Major depressive disorder 6A70.3 Discontinued in Phase 1 [5]
GYKI-52466 DM3YG5P Alzheimer disease 8A20 Terminated [6]
Zonampanel DM70HZD N. A. N. A. Terminated [4]
SORETOLIDE DMTDLHG Convulsion 8A68.Z Terminated [7]
[3H]kainate DMMK7XU Discovery agent N.A. Investigative [8]
DNQX DMQXPA5 Discovery agent N.A. Investigative [9]
RPR-118723 DMLDWCB Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Halothane DM80OZ5 Anaesthesia 9A78.6 Approved [11]
E-2007 DMJDYNQ Diabetic neuropathy 8C0Z Approved [12]
Zopiclone DMPI6Z0 Insomnia 7A00-7A0Z Approved [13]
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [14]
Enflurane DM0YJSB Anaesthesia 9A78.6 Approved [15]
Isoflurane DMY6T31 Anaesthesia 9A78.6 Approved [16]
Bromazepam DMY9TCW Anxiety disorder 6B00-6B0Z Approved [17]
Artemisinin SP DMFETDK Malaria 1F40-1F45 Approved [18]
Dihydroergotoxine DM5D6WZ Alzheimer disease 8A20 Approved [19]
Barbiturate DMJIA6T Anaesthesia 9A78.6 Approved [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor AMPA (GRIA) TTAN6JD NOUNIPROTAC Inhibitor [1]
Glutamate receptor AMPA 1 (GRIA1) TTVPQTF GRIA1_HUMAN Inhibitor [1]

References

1 Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J Med Chem. 1996 Jan 19;39(2):343-6.
2 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3 Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
4 Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11.
5 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
6 New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70.
7 Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24.
8 1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of pot... J Med Chem. 2008 Oct 23;51(20):6614-8.
9 Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
10 Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
11 Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
12 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
13 Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
14 Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
15 Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
16 Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
17 Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
18 GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
19 Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
20 Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.